These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16096815)

  • 1. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview.
    Prohorov T; Klein C; Miniovitz A; Dobronevsky E; Rabey JM
    J Neurol; 2006 Feb; 253(2):171-5. PubMed ID: 16096815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia.
    Reddy S; Factor SA; Molho ES; Feustel PJ
    Mov Disord; 2002 Jul; 17(4):676-81. PubMed ID: 12210856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.
    Fernandez HH; Friedman JH; Jacques C; Rosenfeld M
    Mov Disord; 1999 May; 14(3):484-7. PubMed ID: 10348474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
    Kurlan R; Cummings J; Raman R; Thal L;
    Neurology; 2007 Apr; 68(17):1356-63. PubMed ID: 17452579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
    Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
    Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease.
    Juncos JL; Roberts VJ; Evatt ML; Jewart RD; Wood CD; Potter LS; Jou HC; Yeung PP
    Mov Disord; 2004 Jan; 19(1):29-35. PubMed ID: 14743357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.
    Rabey JM; Prokhorov T; Miniovitz A; Dobronevsky E; Klein C
    Mov Disord; 2007 Feb; 22(3):313-8. PubMed ID: 17034006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis.
    Morgante L; Epifanio A; Spina E; Zappia M; Di Rosa AE; Marconi R; Basile G; Di Raimondo G; La Spina P; Quattrone A
    Clin Neuropharmacol; 2004; 27(4):153-6. PubMed ID: 15319699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.
    Fernandez HH; Okun MS; Rodriguez RL; Malaty IA; Romrell J; Sun A; Wu SS; Pillarisetty S; Nyathappa A; Eisenschenk S
    Int J Neurosci; 2009; 119(12):2196-205. PubMed ID: 19916848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies.
    Fernandez HH; Trieschmann ME; Burke MA; Friedman JH
    J Clin Psychiatry; 2002 Jun; 63(6):513-5. PubMed ID: 12088163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of quetiapine in Parkinson's patients with psychosis.
    Targum SD; Abbott JL
    J Clin Psychopharmacol; 2000 Feb; 20(1):54-60. PubMed ID: 10653209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term use of quetiapine in elderly patients with psychotic disorders.
    Tariot PN; Salzman C; Yeung PP; Pultz J; Rak IW
    Clin Ther; 2000 Sep; 22(9):1068-84. PubMed ID: 11048905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients.
    Fernandez HH; Trieschmann ME; Burke MA; Jacques C; Friedman JH
    Mov Disord; 2003 May; 18(5):510-4. PubMed ID: 12722164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine for insomnia in Parkinson disease: results from an open-label trial.
    Juri C; Chaná P; Tapia J; Kunstmann C; Parrao T
    Clin Neuropharmacol; 2005; 28(4):185-7. PubMed ID: 16062098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group.
    McManus DQ; Arvanitis LA; Kowalcyk BB
    J Clin Psychiatry; 1999 May; 60(5):292-8. PubMed ID: 10362435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of quetiapine for treatment of geriatric psychosis.
    Yang CH; Tsai SJ; Hwang JP
    J Psychopharmacol; 2005 Nov; 19(6):661-6. PubMed ID: 16272189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease.
    Morgante L; Epifanio A; Spina E; Di Rosa AE; Zappia M; Basile G; La Spina P; Quattrone A
    Neurol Sci; 2002 Sep; 23 Suppl 2():S89-90. PubMed ID: 12548358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of quetiapine at low doses on psychosis motor disability and stress of the caregiver in patients with Parkinson's disease].
    Giménez-Roldán S; Navarro E; Mateo D
    Rev Neurol; 2003 Mar 1-15; 36(5):401-4. PubMed ID: 12640589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial.
    McConville B; Carrero L; Sweitzer D; Potter L; Chaney R; Foster K; Sorter M; Friedman L; Browne K
    J Child Adolesc Psychopharmacol; 2003; 13(1):75-82. PubMed ID: 12804128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.